Acurx Pharmaceuticals, Inc. (ACXP)
1.135
0.00 (0.00%)
USD |
NASDAQ |
Oct 23, 16:00
1.135
0.00 (0.00%)
After-Hours: 20:00
Acurx Pharmaceuticals Max Drawdown (5Y) : 99.14% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 99.14% |
| August 31, 2026 | 99.14% |
| July 31, 2026 | 99.14% |
| June 30, 2026 | 99.14% |
| May 31, 2026 | 99.14% |
| April 30, 2026 | 99.14% |
| March 31, 2026 | 99.14% |
| February 28, 2026 | 99.05% |
| Date | Value |
|---|---|
| January 31, 2026 | 98.50% |
| December 31, 2025 | 98.42% |
| November 30, 2025 | 97.62% |
| October 31, 2025 | 97.55% |
| September 30, 2025 | 97.55% |
| August 31, 2025 | 97.19% |
| July 31, 2025 | 96.13% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 77.18% |
| Alnylam Pharmaceuticals, Inc. | 58.17% |
| Anika Therapeutics, Inc. | 83.15% |
| Savara, Inc. | 93.79% |
| Vericel Corp. | 73.97% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -41.79 |
| Beta (5Y) | -2.052 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 137.6% |
| Historical Sharpe Ratio (5Y) | -0.4528 |
| Historical Sortino (5Y) | -1.311 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 40.65% |